Critically Investigating the Potential Benefits and Risks of Aspirin (acetylsalicylic acid) in the Context of Heart Issues Worldwide
The purpose of the review is to study critically in the context of cardiac problems around the world the potential advantages and hazards of aspirin (acetylsalicylic acid). There is no doubt that aspirin gives protection and serious cardiovascular problems may potentially arise. Aspirin is also the cornerstone for preventing thrombotic cardiovascular events, as discovered to be an archetype of non-steroidal anti-inflammatory medications (NSAIDs). A serious discussion has therefore been conducted on the risks and advantages of aspirin.
Yuri Gasparyan et al. (2008) indicated that aspirin is a well-known anti-platelet medication used to prevent cardiovascular events. However, most aspirin patients are at significant risk for thrombotic events mostly due to poor platelet inhibition. The research indicates that 5.5 to 60 percent of patients who take aspirin treatment are usually likely to have aspirin resistance over the long run. There is also little research on the worldwide aspirin resistance. There is evidence that the clinical consequences of aspirin resistance can be examined in cardiovascular conditions, including diabetes, heart failure and other related ailments.
Shah et al. (2012) discovered that patients with a history of heart failure would benefit from using warfarin to decrease the risk of ischemic stroke while investigating whether warfarin or aspirin were beneficial in reducing a fraction of the cardiac ejection rate. The usefulness of aspirin or warfarin is based exclusively on patients’ circumstances. However, initial data show that the usage of aspirin can affect the health of persons with heart failure or other cardiac issues whereas warfarin may boost the possibility to deal more systematically with this problem.
Cattaneo et al. (2004) also stated that worldwide aspirin resistance issues exist. Although the idea of aspirin resistance is not fundamentally defined, ideas are formed that the frequent application of aspirin builds resistance to aspirin which could not be useful to cope with health difficulties. Also, the lowered resistance of aspirin may have minimal impact in the treatment of heart problems and consequences.
In their findings, Ryan et al. (2020) investigated the development of microRNA with changes in arachidonic acid in cardiac and surrounding mesenchymal fatty stem cells treated with or without aspirin.
It has been observed that aspirin is different in individuals and it is not clear whether the large amount of Aspirin taken worldwide to treat cardiovascular events could have a negligible impact on cardiac repair mechanisms. The lack of findings in this respect therefore demands further research and analysis.
Hankey et al. (2006) analysed the rising resistance to aspirin and the failure to inhibit platelet formation by platelet activation and combination of thromboxane A2 in their research. Increased resistance to aspirin may also raise the risk of cardiovascular disease. Some of the potential problems with aspirin resistance could be due to drug interactions, poor doses and generic problems. Aspirin restate can also be treated by lowering the reasons of decreased synthesis of thromboxane. There is, nevertheless, a requirement to clearly and accurately define aspirin resistance by medical testing and to determine cardiovascular risk factors.
Connolly et al. (2018) observed internationally in 33 countries that cardiovascular events are likely to be avoided in those with stable coronary artery disease when adding aspirin with rivaroxaban. The combination of these drugs was predicted to cut deaths by 23 percent and has the advantage of reducing heart disease mortality and morbidity worldwide greatly.
Teerlink et al. (2017) did a study to assess whether a person with a lower expulsion fraction has increased heart failure or hospitalisation. It was observed that aspirin is likely to lead to heart failure in people treated with the angiotensin receptor blocker due of the cyclooxygenase inhibitory effects. The research was conducted on 2305 individuals enrolled in WARCEF and revealed that there were no significant differences between risk factors for heart failure in the patients treated with warfarin and aspirin.
Squizzato et al. (2017) in their research revealed that aspirin alone is not helpful for the treatment and the addition of another antiplatelet medicine, especially for patients who have pre-existing cardiovascular disease, could be useful in creating considerable advantages. The research suggested that it could be advantageous to mix clopidogrel with aspirin to lower the risk of deaths. The research also revealed that the use of these combination medications is helpful in reducing the risk of myocardial infarction and ischemic stroke, although the chance of significant and persistent bleeding increases in comparison to usage of aspirin alone.
Andreotti et al. (2006) supported the use of warfarin aspirin. The study revealed that combination medications are effective to mitigate the potential for additional cardiac problems. However, mild or significant bleeding cases may have to be effectively handled.
In her research, Cleland et al. (2004) concluded that the dangers and benefits of antithrombotic medication have not been identified. The study was carried out in 627 aspirin (300 mg/day) and warfarin in the ratio of 2,5 individuals. The results showed that there are no secondary outcome trends. Significantly, more individuals were hospitalised for cardiovascular reasons leading to heart failure problems with aspirin. The study also showed that aspirin is safe or beneficial in treating people with heart failure or related problems. In addition, the advantages of warfarin in sinus rhythm individuals with heart failure are not demonstrated.
The use of antithrombotic medication is not often evidence-based in patients with heart failure, but often helps to polypharmacy. Devereaux et al. (2014) findings indicated that the usage of aspirin may not lead to death or other deaths but could also increase the bleeding instance, which may lead to other health problems. 110,000 randomised patients undergoing operations were investigated and the usage of aspirin was demonstrated to prevent myocardial infarction and other cardiac problems. A high dose of aspirin has also been demonstrated to be useful in preventing certain cardiac problems.
It was obvious from the discussions that several conclusions suggested that the usage of aspirin is effective to some extent to avoid and mitigate heart problems. In addition, some data indicate that aspirin lone may not be beneficial to treat heart problems and combo medicines may be useful. The usage of aspirin was also associated with a greater risk of minor and significant bleeding. The debate also indicated that a high dose of aspirin may be effective to avoid cardiac failure in patients with a stable myocardial function. Finally, aspirin is recognised to reduce inflammation in patients with numerous health problems. However, the utility of aspirin to reduce heart problems is not entirely established and further investigation is required. The proposal was based on a global analysis and urged further assessment of the advantages and risk factors of aspirin, as different findings emerge for different patient groups.
ANDREOTTI, F., TESTA, L., BIONDI-ZOCCAI, G. G. L., & CREA, F. (2006). Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: An updated and comprehensive meta-analysis of 25 307 patients. European Heart Journal, 27(5), 519-526.
Connolly, S. J., Anand, S. S., HRABAR, A., LUQUEZ, H., MACKINNON, I. J., (2018). Rivaroxaban with or without aspirin in patients with stable coronary artery disease: An international, randomised, double-blind, placebo-controlled trial. The Lancet (British Edition), 391(10117), 205-
Cattaneo, M. (2004). Aspirin and clopidogrel: Efficacy, safety, and the issue of drug resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(11), 1980-1987.
Cleland, J. G. F., Findlay, I., Jafri, S., Sutton, G., Falk, R., Bulpitt, C., Prentice, C., Ford, I., Trainer, A., & Poole-Wilson, P. A. (2004). The Warfarin/Aspirin study in heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure. The American Heart Journal, 148(1), 157-164.
Devereaux, P. J., Mrkobrada, M., Sessler, D. I., Leslie, K., Alonso-Coello, P., Kurz, A., Villar, J. C., Sigamani, A., Biccard, B. M., Meyhoff, C. S., Parlow, J. L., Guyatt, G., Robinson, A., Garg, A. X., Rodseth, R. N., Botto, F., Lurati Buse, G., Xavier, D., Chan, M. T. V., . . . POISE-2 Investigators. (2014). Aspirin in patients undergoing noncardiac surgery. The New England Journal of Medicine, 370(16), 1494-1503.
Hankey, G. J., & Eikelboom, J. W. (2006). Aspirin resistance. The Lancet (British Edition), 367(9510), 606-617
Ruan, D. T., Gao, S., Shelat, H., King, B., & Geng, Y. (2020). Differential expression of microRNA and arachidonic acid metabolism in aspirin-treated human cardiac and peri-cardiac fat-derived mesenchymal stem cells. Vascular Pharmacology, 127, 106651-106651
Shah, S., Parra, D., Rosenstein, R., Chua, D., Nishi, C., Ignaszewski, A., Homma, S., & Thompson, J. L. P. (2012). Warfarin versus aspirin in heart failure and sinus rhythm. The New England Journal of Medicine, 367(8), 771-772.
Squizzato, A., Bellesini, M., Takeda, A., Middeldorp, S., Donadini, M. P., & Squizzato, A. (2017). Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Library, 2017(12),
Teerlink, J. R., Qian, M., Bello, N. A., Freudenberger, R. S., Levin, B., Di Tullio, M. R., Graham, S., Mann, D. L., Sacco, R. L., Mohr, J. P., Lip, G. Y. H., Labovitz, A. J., Lee, S. C., Ponikowski, P., Lok, D. J., Anker, S. D., Thompson, J. L. P., Homma, S., & WARCEF Investigators. (2017). Aspirin does not increase heart Failure Events in heart failure patients: From the WARCEF Trial. JACC. Heart Failure, 5(8), 603.
YURI GASPARYAN, A., WATSON, T., & LIP, G. Y. H. (2008). The role of aspirin in cardiovascular prevention: Implications of aspirin resistance. Journal of the American College of Cardiology, 51(19), 1829-1843